Caligan Partners LP

Holdings History for Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK)

Symbol: ANIK on Nasdaq
Investment type: Equity / Common Stock, par value $0.01 per share
Latest Disclosed Shares Owned: 1,435,130 shares
Security Ownership %: 10%

Shares, Excluding Options vs Price

Value, Excluding Options

Caligan Partners LP ownership in Anika Therapeutics, Inc. Common Stock, par value $0.01 per share (ANIK)

27 Jan 2026 - Caligan Partners LP has filed an SCHEDULE 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,435,130 shares of Anika Therapeutics, Inc. Common Stock, par value $0.01 per share (ANIK). This represents 10% ownership of the company. In their previous filing dated 21 Nov 2025, Caligan Partners LP had reported owning 1,435,130 shares, indicating a new holding.

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
Caligan Partners LP	10%	0%	$13,791,743	1,435,130	0		$9.61	13D/A	23 Jan 2026	27 Jan 2026, 19:29
Caligan Partners LP	10%		$14,365,651	1,435,130			$10.01	13D/A	19 Nov 2025	21 Nov 2025, 09:21

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	1.3%	0%	$13,791,599	1,435,130	0		$9.61	Q4 2025
30 Sep 2025	1.9%	0%	$13,490,222	1,435,130	0		$9.40	Q3 2025
30 Jun 2025	2.9%	0%	$15,183,675	1,435,130	0		$10.58	Q2 2025
31 Mar 2025	4.5%	0%	$21,570,004	1,435,130	0		$15.03	Q1 2025
31 Dec 2024	6%	0%	$23,622,240	1,435,130	0		$16.46	Q4 2024
30 Sep 2024	11%	-0.01%	$35,447,711	1,435,130	-863	-0.06%	$24.70	Q3 2024
30 Jun 2024	8.5%	0%	$36,373,703	1,435,993	0		$25.33	Q2 2024
31 Mar 2024	9.6%	+2.4%	$36,474,222	1,435,993	+354,633	+33%	$25.40	Q1 2024
31 Dec 2023	8.3%	0%	$24,503,618	1,081,360	0		$22.66	Q4 2023
30 Sep 2023	10%	+3.4%	$20,145,737	1,081,360	+361,069	+50%	$18.63	Q3 2023
30 Jun 2023	11%	+0.08%	$18,713,160	720,291	+5,000	+0.7%	$25.98	Q2 2023
31 Mar 2023	14%	+2.5%	$20,543,158	715,291	+123,616	+21%	$28.72	Q1 2023
31 Dec 2022	15%	0%	$17,513,580	591,675	0		$29.60	Q4 2022

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.